Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03563716 · ClinicalTrials.gov registry record · Phase 2
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT03563716 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 135 participants.
The verdict
NCT03563716, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.
Interventions
- DRUG Placebo
- DRUG Atezolizumab
- DRUG Tiragolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2018-08-10 |
| Est. Completion | 2025-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03563716
The ClinicalTrials.gov registry entry for NCT03563716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03563716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03563716 about?
NCT03563716 is a clinical study titled "A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer". This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR muta...
What is the current status of trial NCT03563716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2018-08-10. Estimated completion is 2025-11-14.
What interventions are being tested in trial NCT03563716?
The interventions under investigation include: Placebo (DRUG), Atezolizumab (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT03563716?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.